AB-FUBICA is a compound that is a potent agonist for cannabinoid receptors, displaying notable EC50 values of 21 nM at CB1 and 15 nM at CB2.

IUPAC name
CAS Number1801338-22-6 
Chemical and physical data
Molar mass367.424 g·mol−1


  • What is AB-FUBICA?
  • AB-FUBICA is a synthetic compound known for its pharmacological activity as a potent agonist for cannabinoid receptors, particularly CB1 and CB2.
  • How does AB-FUBICA affect cannabinoid receptors?
  • AB-FUBICA exerts its effects by binding to cannabinoid receptors, specifically CB1 and CB2. It acts as an agonist, triggering a response from these receptors.
  • What are the EC50 values for AB-FUBICA at CB1 and CB2 receptors?
  • AB-FUBICA demonstrates EC50 values of 21 nM at CB1 and 15 nM at CB2 receptors, indicating its high affinity for both receptor types.
  • Is AB-FUBICA associated with any specific effects or uses?
  • As a synthetic compound, AB-FUBICA is primarily associated with research and investigation into its pharmacological properties. Its effects and potential applications are still subjects of study.
  • Is AB-FUBICA a regulated substance?
  • The legal status of AB-FUBICA varies by country and region. It is essential to be aware of and comply with the specific laws and regulations governing the possession, distribution, and use of this compound in your area.
  • Are there safety concerns related to AB-FUBICA?
  • The safety profile of AB-FUBICA has yet to be comprehensively established. As with all synthetic compounds, its use is discouraged due to potential health risks and a lack of safety data.
  • Where can I find more information about AB-FUBICA?
  • To access comprehensive information regarding AB-FUBICA, including its chemical properties, potential risks, and legal status, consider consulting reliable sources such as government health agencies, scientific publications, and organizations specializing in substance research.


  1. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, and their colleagues published a groundbreaking study in September 2015. They delved into the “Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs,” examining compounds like AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. Their findings were documented in the esteemed journal “ACS Chemical Neuroscience,” Volume 6, Issue 9, pages 1546–1559. You can explore further details by referring to doi:10.1021/acschemneuro.5b00112. The PMID for this publication is 26134475.
  2. In November 2015, Qian Z, Hua Z, Liu C, and Jia W contributed to the field of forensic toxicology by identifying “Four types of cannabimimetic indazole and indole derivatives.” These novel psychoactive substances included ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA. Their comprehensive research was published in the “Forensic Toxicology” journal, with the article spanning pages 133–143. You can access the study via doi:10.1007/s11419-015-0297-2, and it is also available on PMC (PubMed Central) with the identifier PMC 4705129. The PMID for this publication is 26793280.

Leave a Comment

Your email address will not be published. Required fields are marked *